TB R&D Weekly Update: Tyrosine Kinases as Therapeutic Targets against TB

Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis. Cell Host Microbe. 2011 Nov 17;10(5):475-85.

This week’s article looks at host factors that contribute to the ability of Mycobacterium tuberculosis (Mtb) to enter and survive within macrophages. The authors explore the role of tyrosine kinases (TKs) as a mediator for Mtb and the use of an inhibitor of TKs to act against Mtb and related bacteria. Key points from the article are:

  • Data from experiments using TK inhibitors and cell lines from knockout animals show that there is a role for specific TKs in Mtb and related bacteria’s processes for entry and intracellular survival. Also, it appears multiple kinases mediate intracellular survival within macrophages.
  • Imatinib, an inhibitor of some TKs and used in cancer therapy, was shown to reduce bacterial loads in macrophages and mice infected with Mtb or M. marinum. Imatinib also seems to have synergy with drugs like rifampicin and rifabutin.
  • There has been low toxicity reported in patients although there is some reported toxicity in patients taking imatinib with long-term exposure. This may suggest looking at imatinib as a therapeutic against active TB or reactivated TB. The benefit of targeting the host with imatinib is that the bacteria would need to make a major adaptation to develop resistance and also could confer some protection to current first-line drugs by reducing the bacterial burden below the spontaneous mutation frequency.

Additional TB R&D News:

SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time

Hyderabad scientists discover TB bacteria killer

Eli Lilly and Company Provides IDRI with Additional Funding for Identification of New Tuberculosis Therapies

Tuberculosis – Novel Tools And Coordination Required

Webcams Connect TB Patients to Public Clinic for Treatment Compliance

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...